Kane Kathleen E, Cone David C
Division of EMS, Section of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut 06519, USA.
J Emerg Med. 2004 Nov;27(4):371-7. doi: 10.1016/j.jemermed.2004.04.018.
Many Emergency Medical Services (EMS) systems have adopted epinephrine auto-injector (EAI) use by Basic Life Support (BLS) personnel, and several states now require that BLS personnel be trained and authorized to use EAIs. The objectives of this observational study were: 1) to examine EMS case definitions of allergy/anaphylaxis, 2) to ascertain the incidence of EMS calls for allergy/anaphylaxis and administration of epinephrine, and 3) to quantify the rate of deaths due to anaphylaxis. Data were solicited by e-mail, mail, and telephone from National Association of State EMS Directors (NASEMSD) members, state EMS offices, and state medical examiner and vital statistics offices. Simple descriptive statistics were used to analyze the data. The following was found: 1) there is no standardization of case definitions among states. Some use the terms "allergic reaction" and "anaphylaxis" in EMS protocols without definition, whereas others provide lengthy, specific definitions, with detailed criteria for epinephrine administration; 2) excluding two outliers at 0.04% and 3.9%, nine EMS system databases totaling over 2.8 million runs contained between 0.34% and 0.82% of runs for allergy/anaphylaxis. Seven of these databases reported on epinephrine administration, with rates between 0.16% and 31.1%, and four of the seven clustered between 8.8% and 14.8%. There was little uniformity in the data provided by seven states on deaths due to anaphylaxis, with rates from 0% to 0.94%. Although limited by the lack of data from many states, roughly 0.5% of EMS runs are for allergy/anaphylaxis complaints, with epinephrine administered in roughly one-tenth of these. State death rates from anaphylaxis vary considerably, with rates from 0% to 0.94% reported.
许多紧急医疗服务(EMS)系统已采用基础生命支持(BLS)人员使用肾上腺素自动注射器(EAI),并且现在有几个州要求BLS人员接受培训并获得使用EAI的授权。这项观察性研究的目的是:1)检查EMS对过敏/过敏反应的病例定义,2)确定因过敏/过敏反应而呼叫EMS并使用肾上腺素的发生率,3)量化因过敏反应导致的死亡率。通过电子邮件、邮件和电话向州紧急医疗服务主任协会(NASEMSD)成员、州EMS办公室以及州法医和生命统计办公室征求数据。使用简单的描述性统计方法分析数据。结果如下:1)各州之间病例定义没有标准化。一些州在EMS协议中使用“过敏反应”和“过敏反应”这两个术语但未定义,而其他州则提供冗长、具体的定义以及肾上腺素给药的详细标准;2)排除0.04%和3.9%这两个异常值后,九个EMS系统数据库总计超过280万次运行,其中过敏/过敏反应的运行次数占0.34%至0.82%。其中七个数据库报告了肾上腺素的使用情况,使用率在0.16%至31.1%之间,七个中的四个集中在8.8%至14.8%之间。七个州提供的因过敏反应导致死亡的数据几乎没有一致性,死亡率从0%到0.94%不等。尽管受到许多州数据缺乏的限制,但大约0.5%的EMS运行是关于过敏/过敏反应投诉的,其中大约十分之一会使用肾上腺素。各州因过敏反应导致的死亡率差异很大,报告的死亡率从0%到0.94%不等。